About BioNTech
BioNTech is a publicly listed company based in Mainz (Germany) founded in 2008 by Christoph Huber and Ozlem Tureci. Immunotherapeutics for cancer and other diseases are developed. BioNTech has raised $805.99 million across 12 funding rounds from investors including Fidelity Investments, Mirae Asset and Sanofi. The company has 6,770 employees. BioNTech has completed 5 acquisitions, including Biotheus, CureVac and InstaDeep. Its website biontech.com draws about 115 thousand monthly visits. BioNTech offers products and services including COMIRNATY and mRNA Cancer Immunotherapies. Its focus areas include Life Sciences, Immunotherapy, Diversified and Immunology. Its legal entity is BioNTech SE.
Company details
BioNTech was established in 2008 in Mainz, Germany, within the biotechnology sector. Immunotherapeutics targeting cancer and additional diseases are developed, with an oncology pipeline encompassing mRNA-based treatments, modified cell therapies, antibodies, and small molecule immunomodulators. Optimization for specific action mechanisms, precise targeting, potency, and efficacy is emphasized in these efforts. Operations center on advancing therapeutic innovations for clinical applications.
- Headquarters Mainz, Germany
- Employees 6,770
- Founders Christoph Huber, Ozlem Tureci
- Stage Public
- SectorsHealthcare
- Website category Heavy Industry and Engineering · Agriculture
- Email••••••••
- Phone•••• ••••
- Website biontech.com/int/en/home.html
- Social LinkedIn X
- Legal Name Biontech Se Sponsored Adr
- Annual Revenue$3.24 B (USD)8.84as on Dec 31, 2025
- Net Profit-$1.28 B (USD)-78.17as on Dec 31, 2025
- EBITDA-$300.99 M (USD)19.44as on Dec 31, 2025
- Total Equity Funding$805.99M (USD)
in 12 rounds
- Latest Funding Round$150M (USD), Post-IPO
Apr 2022
- InvestorsFidelity Investments
& 18 more
- Employee Count6,770
- Investments & AcquisitionsBiotheus
& 4 more
Products & Services of BioNTech
BioNTech offers a comprehensive portfolio of products and services, including COMIRNATY and mRNA Cancer Immunotherapies.
mRNA vaccine for preventing COVID-19 infections
Immunotherapies targeting cancer cells via mRNA technology
Funding Insights of BioNTech
BioNTech has successfully raised a total of $805.99M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $805.99M
- Total Rounds 12
- Last Round Post-IPO — $150M
- Investors Count 19
Latest 10 of 12 funding rounds of BioNTech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $150M | Post-IPO | – | – | – |
| Sep 2020 | $444.77M | Post-IPO | – | – | |
| Jun 2020 | $250M | Post-IPO | – | – | |
| Mar 2020 | $133.3M | Post-IPO | – | – | |
| Jul 2019 | $325M | Series B | – | Fidelity Investments | |
| Jun 2019 | Series C | – | – | ||
| Jan 2019 | $90.99M | Series A | – | – | |
| Aug 2018 | $120M | Series A | – | Pfizer Venture Investments | – |
| Jan 2018 | $270M | Series A | – | Redmile Group | |
| Nov 2015 | $440,807 | Grant | – | – |
19 investors in total: 19 institutional.
Investors in BioNTech
BioNTech has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Mirae Asset and Sanofi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
An investment platform is provided for diverse sectors and geographies. | 1974 | temasek.com.sg | Singapore, Singapore | |
Jebsen Capital is engaged in multi-strategy investments for Jebsen Group. | 1895 | jebsen-capital.com | Hong Kong, Hong Kong | |
VC firm funding companies in China and the US | bvcf.com | Huangpu, China | ||
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Venture capital is focused on healthcare by Pfizer's investment arm. | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | ||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Venture capital investments in technology companies are managed by MIG Fonds. | mig-fonds.de | Germany | ||
Investor details for BioNTech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioNTech
462 people are tracked at BioNTech (292 in leadership, 5 in board & advisors, 165 in team); the tracked headcount is 6,770.
| Name | Role | Group |
|---|---|---|
Christoph Huber | Co-Founder & Managing Director | Leadership |
Ozlem Tureci | Co-Founder | Leadership |
Oliver Ries | Director Quality / Qualified Person (qp) | Leadership |
Pedro L. Alonso | SVP, Science & Medicine and Head of Global Health Office | Leadership |
Mia D. | Director, Global Medical Affairs | Leadership |
Penny Turner | Senior Director, Business Planning & Analysis | Leadership |
Dr. Risha Sharma | Associate Director - Compliance & QPPV Office | Leadership |
Ugur Sahin | CEO | Leadership |
Özlem Türeci | Chief Medical Officer | Leadership |
Aneto Okeke | Site Head & Managing Director | Leadership |
Meghan Weiler | Director, Total Rewards | Leadership |
Xiuxia Sun | Director | Leadership |
Vladislava Chalei | Director, Strategy And Corporate Development | Leadership |
Kamlesh Prabhu | Director Medical Safety | Leadership |
Jason Stone | Senior Director, Quality Operations And Compliance | Leadership |
Kannan Krishnamurthy | Senior Director, Business Development | Leadership |
Esther Riga | Associate Director Quality Control | Leadership |
Dipa Kumar | Director/platform Lead Clinops, Biontech | Leadership |
Manuel Boll | Associate Director Biontainer Performance Management | Leadership |
Nadine Hennig | Associate Director Planning | Leadership |
442 more people are available in the full profile.
Complete people profiles for BioNTech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of BioNTech
BioNTech is a publicly listed company on the NASDAQ with ticker symbol BNTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Dec 2020
- Listed onVIE: BNTX
- Listed entityBioNTech SE Sponsored ADR
- Exchange sectorHealth technology
- ISINUS09075V1026
- Share price$89.01 (-7.13% on the day) · 2026-10-13
- Market capitalisation$22.36B
- EPS (diluted, trailing year)$-7.85
- Volume (last session)1,951,721
Financials of BioNTech
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $3.24B | -$1.28B | -$301.0M |
| 2024 | $2.98B | -$719.6M | -$373.6M |
| 2023 | $4.13B | $1.01B | $1.18B |
| 2022 | $18.19B | $9.92B | $16.10B |
| 2021 | $22.43B | $12.17B | $20.93B |
Detailed financial statements for BioNTech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioNTech
BioNTech has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Biotheus, CureVac and InstaDeep.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
mRNA-based therapeutics against cancer and infectious diseases are developed. | curevac.com | Tubingen, Germany | 2000 | Jun 2025 | $1.25B | |
Developer of antibody-based therapeutics for cancer treatment | biotheus.com | Zhuhai, China | 2018 | Nov 2024 | $800M | |
AI and cloud-based automation solutions are provided for organizational optimization. | instadeep.com | London, United Kingdom | 2015 | Jan 2023 | $549M | |
Alternatives to antibiotics are developed via phage therapy expertise. | phagomed.com | Vienna, Austria | 2016 | Nov 2021 | •••• | |
Tumor-specific neoantigens are identified for personalized cancer vaccine development. | neontherapeutics.com | Cambridge, United States | 2015 | Jan 2020 | •••• |
Complete acquisition details for BioNTech
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of BioNTech
9 dated milestones of BioNTech across 17 years, from founding to its latest funding, stage changes and deals.
- Founded BioNTech is founded.
- Funding First funding round.
- Acquisition Acquires Neon Therapeutics.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires PhagoMed.
- Funding Latest funding round, Post-IPO, of $150.0M.
- Acquisition Acquires InstaDeep.
- Acquisition Acquires Biotheus.
- Acquisition Acquires CureVac.
Web traffic of BioNTech
The website of BioNTech (biontech.com) receives about 115K visits a month and ranks #329,096 among all websites worldwide, #3,788 in Agriculture.
- Monthly visits115K
▼ 2% vs previous month
- Unique visitors51.7K
per month
- Global rank#329,096
among all websites
- Category rank#3,788
Heavy Industry and Engineering · Agriculture
- Bounce rate46%
- Pages per visit2.4
- Average visit1 min 14 sec
- DevicesDesktop 48% · Mobile 52%
Websites whose visitors overlap most with BioNTech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
ne1024.dyndns.org | ne1024.dyndns.org | 100% | – | ||
eptcorp.com | eptcorp.com | 59% | – | ||
| cescenter.com | 59% | View details | |||
| questortech.com | 58% | 2.2K | #9,444,304 | View details | |
| saarbruecker-stadtwerke.de | 55% | 7.1K | #3,248,530 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for BioNTech
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biontech
Complete news archive for BioNTech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioNTech
BioNTech was founded in 2008.
BioNTech is headquartered in Mainz, Germany. It is registered at Mainz, Rhineland-palatinate, Germany.
BioNTech is a funded company, having raised a total of $805.99M across 12 funding rounds to date. The company's 1st funding round was a Grant of $440.81K, raised on Jun 2008.
BioNTech has 6,770 employees.
Annual revenue of BioNTech is $3.24B as on Dec 31, 2025.
BioNTech was established in 2008 in Mainz, Germany, within the biotechnology sector. Immunotherapeutics targeting cancer and additional diseases are developed, with an oncology pipeline encompassing mRNA-based treatments, modified cell therapies, antibodies, and small molecule immunomodulators. Optimization for specific action mechanisms, precise targeting, potency, and efficacy is emphasized in these efforts. Operations center on advancing therapeutic innovations for clinical applications.
BioNTech offers COMIRNATY and mRNA Cancer Immunotherapies.
Yes, BioNTech is publicly traded on NASDAQ under the ticker symbol BNTX.
BioNTech has 19 investors. Key investors include Fidelity Investments, Mirae Asset, Sanofi, Fosun Pharmaceutical, and Gates Foundation.
BioNTech operates through Biontech Se.
The website of BioNTech receives about 115 thousand visits a month and ranks #329,096 among all websites worldwide.